CoChat

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

BACKGROUND: Synaptic degeneration is an early pathogenic event in Alzheimer's disease, associated with cognitive impairment and disease progression. Cerebrospinal fluid biomarkers reflecting synaptic integrity would be highly valuable tools to monitor synaptic degeneration directly in patients. We previously showed that synaptic proteins such as synaptotagmin and synaptosomal-associated protein 25 (SNAP-25) could be detected in pooled samples of cerebrospinal fluid, however these assays were not sensitive enough for individual samples. RESULTS: We report a new strategy to study synaptic pathology by using affinity purification and mass spectrometry to measure the levels of the presynaptic protein SNAP-25 in cerebrospinal fluid. By applying this novel affinity mass spectrometry strategy on three separate cohorts of patients, the value of SNAP-25 as a cerebrospinal fluid biomarker for synaptic integrity in Alzheimer's disease was assessed for the first time. We found significantly higher levels of cerebrospinal fluid SNAP-25 fragments in Alzheimer's disease, even in the very early stages, in three separate cohorts. Cerebrospinal fluid SNAP-25 differentiated Alzheimer's disease from controls with area under the curve of 0.901 (P < 0.0001). CONCLUSIONS: We developed a sensitive method to analyze SNAP-25 levels in individual CSF samples that to our knowledge was not possible previously. Our results support the notion that synaptic biomarkers may be important tools for early diagnosis, assessment of disease progression, and to monitor drug effects in treatment trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1750-1326-9-53

Cites

Statistics

Figures

Figure 1 Targeted SRM-MS analyses of SNAP-25 in human brain. Individual values for the SRM-MS measured ratios (endogenous peptide/labeled peptide standard) of immunoprecipitated [antibodies SP12 (A-B) and SMI81 (C) SNAP-25, in biochemically fractionated membrane-bound (A) and membrane-raft associated (B) and soluble (C), extract of superior parietal gyrus from controls (N = 15) and patients with Alzheimer’s disease (N = 15). The lower, upper and middle lines of the error bars correspond to the 25th and 75th percentiles and medians, respectively. SMI81 recognizes the extreme N-terminus of SNAP-25, especially when it’s N-terminal acetylated. The exact epitope of SP12 is unknown.
Figure 1 Targeted SRM-MS analyses of SNAP-25 in human brain. Individual values for the SRM-MS measured ratios (endogenous peptide/labeled peptide standard) of immunoprecipitated [antibodies SP12 (A-B) and SMI81 (C) SNAP-25, in biochemically fractionated membrane-bound (A) and membrane-raft associated (B) and soluble (C), extract of superior parietal gyrus from controls (N = 15) and patients with Alzheimer’s disease (N = 15). The lower, upper and middle lines of the error bars correspond to the 25th and 75th percentiles and medians, respectively. SMI81 recognizes the extreme N-terminus of SNAP-25, especially when it’s N-terminal acetylated. The exact epitope of SP12 is unknown.CC BY · PubMed Central
Figure 2 Sequence coverage of SNAP-25. (A) Heat map for the relative LC-MS signal intensities of individual tryptic peptides from SNAP-25B. Biochemically fractionated soluble proteins of superior parietal gyrus from controls (N = 7) and patients with Alzheimer’s disease (N = 9) were immunoprecipitated with SMI81. High resolution LC-MS ion chromatograms of all peptides identified as belonging to SNAP-25B were extracted. An increase of signal intensity is seen as a blue to red shift. (B) Amino acid sequences for SNAP-25B and SNAP-25A. Soluble endogenous forms identified by top-down LC-MS/MS analysis are indicated by arrows above the sequences. Differences between SNAP-25B and SNAP-25A are indicated by boxes. Amino acids belonging to tryptic peptides identified by LC-MS/MS are labeled bold. The two glutamines (Q) indicated “ionic 0 layer” contribute together with a syntaxin glutamine (Q), and a VAMP arginine (R) to the highly conserved 3Q:1R motif at the core of the SNARE complex.
Figure 2 Sequence coverage of SNAP-25. (A) Heat map for the relative LC-MS signal intensities of individual tryptic peptides from SNAP-25B. Biochemically fractionated soluble proteins of superior parietal gyrus from controls (N = 7) and patients with Alzheimer’s disease (N = 9) were immunoprecipitated with SMI81. High resolution LC-MS ion chromatograms of all peptides identified as belonging to SNAP-25B were extracted. An increase of signal intensity is seen as a blue to red shift. (B) Amino acid sequences for SNAP-25B and SNAP-25A. Soluble endogenous forms identified by top-down LC-MS/MS analysis are indicated by arrows above the sequences. Differences between SNAP-25B and SNAP-25A are indicated by boxes. Amino acids belonging to tryptic peptides identified by LC-MS/MS are labeled bold. The two glutamines (Q) indicated “ionic 0 layer” contribute together with a syntaxin glutamine (Q), and a VAMP arginine (R) to the highly conserved 3Q:1R motif at the core of the SNARE complex.CC BY · PubMed Central
Figure 3 Targeted HR-SIM-MS analyses of SNAP-25 in human CSF. Individual values for the HR-SIM-MS measured peak area ratios ([endogenous peptide/labeled peptide standard] multiplied by 10,000) of immunoprecipitated (SMI81 antibody) SNAP-25 in CSF samples within German cohort (A-C), Swedish cohort I (D-F), Swedish cohort II (G-I), and the entire group of Alzheimer’s disease (N = 36) and controls (N = 32) (J-L). The nine panels depict the measured levels of three N-terminal tryptic peptides of SNAP-25, Ac-2-16 (A, D, G, J), 17-31 (B, E, H, K), and 32-40 (C, F, I, L).
Figure 3 Targeted HR-SIM-MS analyses of SNAP-25 in human CSF. Individual values for the HR-SIM-MS measured peak area ratios ([endogenous peptide/labeled peptide standard] multiplied by 10,000) of immunoprecipitated (SMI81 antibody) SNAP-25 in CSF samples within German cohort (A-C), Swedish cohort I (D-F), Swedish cohort II (G-I), and the entire group of Alzheimer’s disease (N = 36) and controls (N = 32) (J-L). The nine panels depict the measured levels of three N-terminal tryptic peptides of SNAP-25, Ac-2-16 (A, D, G, J), 17-31 (B, E, H, K), and 32-40 (C, F, I, L).CC BY · PubMed Central
Figure 4 ROC curve analysis of SNAP-25 in human CSF. ROC curve analysis for SNAP-25 32-40 (turquoise), SNAP-25 17-31 (green), SNAP-25 Ac-2-16 (black) Aβ1-42 (orange), T-tau (purple) and P-tau181 (yellow) in CSF for differentiation of Alzheimer’s disease patients from controls in the entire subject material. The area under the curve (95% confidence interval) was 0.901 (0.828-0.974) (P < 0.0001), 0.808 (0.703-0.913) (P < 0.0001), 0.772 (0.659-0.885) (P < 0.001), 0.881 (0.802-0.960) (P < 0.0001), 0.933 (0.873-0.994) (P < 0.0001), and 0.916 (0.844-0.987) (P < 0.0001), respectively.
Figure 4 ROC curve analysis of SNAP-25 in human CSF. ROC curve analysis for SNAP-25 32-40 (turquoise), SNAP-25 17-31 (green), SNAP-25 Ac-2-16 (black) Aβ1-42 (orange), T-tau (purple) and P-tau181 (yellow) in CSF for differentiation of Alzheimer’s disease patients from controls in the entire subject material. The area under the curve (95% confidence interval) was 0.901 (0.828-0.974) (P < 0.0001), 0.808 (0.703-0.913) (P < 0.0001), 0.772 (0.659-0.885) (P < 0.001), 0.881 (0.802-0.960) (P < 0.0001), 0.933 (0.873-0.994) (P < 0.0001), and 0.916 (0.844-0.987) (P < 0.0001), respectively.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 40 · Cited by 293

Research works printed but not linked: 1

  1. 10.1002/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2 · doi:10.1002/(sici)1522-2683(19990301)20:3<431::aid-elps431>3.0.co;2-2

Metadata

Authors
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., & Öhrfelt, A.
Affiliations
  • University of Gothenburg (SE)
  • University of British Columbia (CA)
  • Heidelberg University (DE)
  • Lund University (SE)
  • National Hospital for Neurology and Neurosurgery (GB)
Corresponding author
Brinkmalm, Ann
Venue
Molecular Neurodegeneration
Published
2014
Volume
9
Issue
1
Pages
53
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2142194239
Cited by
293
References
40
Citations by year
2026: 19 · 2025: 26 · 2024: 33 · 2023: 19 · 2022: 42 · 2021: 22 · 2020: 31 · 2019: 29 · 2018: 24 · 2017: 16 · 2016: 22 · 2015: 10
FWCI
10.54
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • cIRcle (University of British Columbia) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
  • Open Collections
Funders
  • Gun och Bertil Stohnes Stiftelse
  • Wolfson Foundation
  • Bundesministerium für Bildung und Forschung
  • Knut och Alice Wallenbergs Stiftelse
  • Vetenskapsrådet
  • Åhlén-stiftelsen
  • Swedish Brain Power
  • Svenska Läkaresällskapet
  • Demensfonden
  • Canadian Institutes of Health Research (CBG101827, MOP‐14037)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Keywords
SNAP-25, cerebrospinal fluid biomarkers, synaptic degeneration, Alzheimer's disease, presynaptic proteins, early diagnosis, disease progression monitoring, synaptotagmin
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Chromatography, Liquid, Female, Humans, Male, Middle Aged, Nerve Degeneration, ROC Curve, Sensitivity and Specificity, Synapses, Biomarkers, Area Under Curve, Immunoprecipitation, Synaptosomal-Associated Protein 25, Tandem Mass Spectrometry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/1750-1326-9-53
The paper
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., & Öhrfelt, A. (2014). SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-9-53

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.